Why Did The NeuroSense (NRSN) Stock Rise By 12% In Extended Trading?

0
143

Following the release of a business update, NeuroSense Therapeutics Ltd. (NASD: NRSN) increased 12.58% to $1.70 in after-hours trading on Thursday.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


What kind of upgrade has NRSN offered?

This month, NeuroSense (NRSN) released a business update for the three months that concluded on September 30, 2022.

Enrollments of patients in the US and Italy

The clinical development strategy for PrimeC, which is presently being assessed in PARADIGM, a double-blind, placebo-controlled, multi-center Phase 2b clinical study, saw NeuroSense reach numerous objectives during the third quarter. More than 40% of the patients required to finish the experiment have already signed up.

The company’s investigational new drug (IND) has been approved by the Food and Drug Administration (FDA) (IND). Additionally, NRSN obtained endorsement from the Italian Medicines Agency (AIFA). NRSN is anticipated to start for PARADIGM in the U.S. and Europe in the next weeks after the acceptance of both of these patent enrollment applications.

PK Studies with Multiple Doses

Results from a multi-dose pharmacokinetic (PK) research were made public by NRSN in Q3 (NCT05436678). The PK open-label, randomized, multi-dose, three-treatment, three-period crossover study assessed the impact of food on PrimeC’s bioavailability in adult subjects in the U.S. under an FDA-cleared IND protocol in comparison to the bioavailability of co-administered ciprofloxacin tablets and celecoxib capsules.

Based on the findings, NRSN believes PrimeC’s PK profile supports the formulation’s extended-release features since the active ingredients’ concentrations have been synchronized in an effort to possibly optimize their synergistic effects.

Conferences and publications

Results from NeuroSense’s Phase 2a study were presented in an article co-authored by the scientific team at NeuroSense and top ALS researchers, titled “Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS,” which was printed in the peer-reviewed journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

More from the NRSN

Through ALS conferences held during and after the conclusion of Q3, NeuroSense (NRSN) enhanced current relationships and investigated potential research collaborations. The TRICALS Consortium 2022 Masterclass, the largest European research initiative to find a cure for ALS, was held in the Netherlands and featured presentations on the use of biomarkers in ALS clinical trials by NRSN’s Chief Medical Officer, Ferenc Tracik, MD, and Head of Scientific Program, Shiran Zimri, Ph.D.

LEAVE A REPLY

Please enter your comment!
Please enter your name here